Pharma Marketing Network

DECEMBER 17, 2021

The pharma industry has been slower to embrace digital technologies than other less-regulated sectors but the COVID-19 pandemic has greatly changed this long-standing mindset. In 2020 and 2021, we saw pharma forced to become more flexible and open-minded than ever before. HCP Engagement and Pharma Salesforces.

Customer Service 105

Customer Service Vaccines Communication 105

pharmaphorum

SEPTEMBER 18, 2020

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company’s story, from its creation as a merger of two equals, to its recent major restructuring and its drives in cutting-edge oncology and COVID-19. Responding to these pressures, Astra began to look for partners.

Vaccines 116

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 116

PharmaShots

FEBRUARY 21, 2023

Shots: Integrating scintigraphy with therapeutics, radiopharmaceutical companies have emerged profoundly in the past few decades. With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market. threshold by 2026. threshold by 2026.

FDA 56

FDA Dosage Pharmaceutical Companies Pharmaceutical Companies 56

PharmaShots

MARCH 29, 2023

Shots: Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years. Currently, the drug is not accessible in generic form.

FDA 49

FDA Chemotherapy Immunization Dosage 49

PharmaShots

MAY 24, 2023

Revenue Analysis1 Trikafta/Kaftrio is developed and commercialized by Vertex Pharmaceuticals. In 2022, Vertex Pharma’s net product revenue spiked by 18%, vs. 2021, mainly due to influx of Trikafta in multiple countries internationally and the growing performance of Trikafta in the U.S.

Insurance Coverage 56

Insurance Coverage FDA Hospitals Dosage 56

PharmaShots

APRIL 25, 2023

This year Roche has secured the top position with a total R&D Expenditure of $15.20B, followed by Johnson & Johnson and AstraZeneca PharmaShots presents the Top 20 RNAi therapeutic companies based on their R&D Expenditure in the year 2022 R&D Expenditure: $43.1M R&D Expenditure: $84.4M

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40

PharmaShots

JANUARY 31, 2023

Shots: Immutable capital demands and high-spending drug development plans are the most common drivers in encouraging fully-fledged private healthcare companies to go public. The company bagged its $6.3M LP-310, another lead asset of the company received FDA Type-B Pre-IND guidance recently for Oral Lichen Planus. of Shares: 1.5M

Vaccines 40

Vaccines Immunization FDA 40

PharmaShots

APRIL 12, 2023

Shots: Biopharma companies have kept themselves afloat in the ocean of uncertainties by overcoming the hurdles of unmet demands, procurement, and maintaining a constant supply chain. The company's mRNA platform comprises advances across three components, i.e., mRNA, delivery, and the manufacturing process.

Vaccines 64

Vaccines FDA Pharmaceutical Companies Pharmaceutical Companies 64

ISPE

MAY 8, 2023

Message from the Chair: Meeting the Strategic Plan Trudy Patterson Mon, 05/08/2023 - 20:16 Insights May / June 2023 Message from the Chair: Meeting the Strategic Plan Michael L. Rutherford 1 May 2023 It is hard to believe that by the time this column is published, my term as Chair will be half over.

Documentation 52

Documentation 52

PharmaShots

APRIL 26, 2023

PharmaShots presents an informative take on the key features of Dupixent with a detailed analysis of its revenue, clinical trials, alternatives, and approvals. Both companies collaborated on the global development and commercialization of Dupixent, Kevzara, and itepekimab (the "Antibody Collaboration"). mL, 100 mg/0.67

Dosage 56

Dosage FDA 56

ISPE

JULY 6, 2023

Considerable uncertainty exists, however, among manufacturers regarding the costs and benefits of CM technology, including several risks that, so far, are holding companies back from making the leap to CM. Leveraging SRM Concepts for CM SRM provides a formalized structure about the way in which a company manages its various risks.

Insurance 52

Insurance Documentation Pharmaceutical Companies Pharmaceutical Companies 52

ISPE

MARCH 6, 2023

Challenges for Net Zero Carbon Pharmaceutical Manufacturing Trudy Patterson Mon, 03/06/2023 - 12:40 Features March / April 2023 Challenges for Net Zero Carbon Pharmaceutical Manufacturing Keith M. This study showed that only 9% of the companies currently have targets aligned with a 1.5°C But most companies do not.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Compounding 52